Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anny Shai

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Neuro-Oncology|September 27, 2023
A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomasAtsuro Saijo, Hirokazu Ogino, Nicholas A Butowski, et al.
The Journal of Clinical Investigation|December 9, 2021
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomasHirokazu Ogino, Jennie W Taylor, Takahide Nejo, et al.
Cell|January 19, 2024
Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspectiveRadhika Mathur, Qixuan Wang, Patrick G Schupp, et al.
Acta Neuropathologica|December 11, 2023
"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockadeSara Hadad, Rohit Gupta, Nancy Ann Oberheim Bush, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2023
Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade GliomaShawn L Hervey-Jumper, Yalan Zhang, Joanna J Phillips, et al.
Neuro-Oncology|November 19, 2024
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responsesCalixto-Hope G Lucas, Nadeem N Al-Adli, Jacob S Young, et al.
JAMA Oncology|February 7, 2020
Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed GlioblastomaAnnette M Molinaro, Shawn Hervey-Jumper, Ramin A Morshed, et al.
Acta Neuropathologica|August 9, 2022
Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1Calixto-Hope G Lucas, Emily A Sloan, Rohit Gupta, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Neuro-Oncology|September 27, 2023
A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomasAtsuro Saijo, Hirokazu Ogino, Nicholas A Butowski, et al.
The Journal of Clinical Investigation|December 9, 2021
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomasHirokazu Ogino, Jennie W Taylor, Takahide Nejo, et al.
Cell|January 19, 2024
Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspectiveRadhika Mathur, Qixuan Wang, Patrick G Schupp, et al.
Acta Neuropathologica|December 11, 2023
"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockadeSara Hadad, Rohit Gupta, Nancy Ann Oberheim Bush, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2023
Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade GliomaShawn L Hervey-Jumper, Yalan Zhang, Joanna J Phillips, et al.
Neuro-Oncology|November 19, 2024
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responsesCalixto-Hope G Lucas, Nadeem N Al-Adli, Jacob S Young, et al.
JAMA Oncology|February 7, 2020
Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed GlioblastomaAnnette M Molinaro, Shawn Hervey-Jumper, Ramin A Morshed, et al.
Acta Neuropathologica|August 9, 2022
Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1Calixto-Hope G Lucas, Emily A Sloan, Rohit Gupta, et al.
Pageof 3